Clinical Trial Detail

NCT ID NCT01698918
Title Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Exemestane

Everolimus + Letrozole

Age Groups: adult

Additional content available in CKB BOOST